Series B funding pushes Trinity toward clinical trials

Transcatheter Technologies announced today that it has closed €2.6m of Series B funding round.

The Regensburg, Germany-based company is developing Trinity, a fully repositionable device for transcatheter aortic valve implantation.

Existing investors and undisclosed new investors participated in this funding round, which will be used to enter clinical trials.

Prof Dr Thomas Walther, director of cardiac surgery at the Kerckhoff Clinic in Bad Nauheim, Germany, said, ‘Having proven safe implantation and complete repositioning of Trinity in the experimental model, the device offers promising perspectives for clinical practice in the future.’